Skip to Main content Skip to Navigation
Journal articles

Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Abstract : In clinical studies, thromboprophylaxis with low-molecular-weight heparins (LMWHs) has been demonstrated to reduce the risk of venous thromboembolism and to improve outcomes in cancer patients. Moreover, preclinical models have previously suggested that LMWHs may also offer additional benefits through direct antitumor properties. However, the optimal doses of LMWHs that may prevent both cancer-related thrombosis and tumor development are yet unknown.
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-01451070
Contributor : Françoise Dignat-George <>
Submitted on : Tuesday, January 31, 2017 - 4:01:17 PM
Last modification on : Monday, September 23, 2019 - 3:52:04 PM

Identifiers

Collections

Citation

Corinne Frere, Soraya Mezouar, Léa Plantureux, Lydie Crescence, Laurence Panicot-Dubois, et al.. Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor. Journal of Thrombosis and Haemostasis, Wiley, 2016, 14, pp.76-76. ⟨10.1016/S0049-3848(16)30167-0⟩. ⟨hal-01451070⟩

Share

Metrics

Record views

76